Abstract
Targeting PIM kinases to oppose hypoxia-mediated therapeutic resistance.
Highlights
PIM kinase family members have been implicated as important factors in the progression and prognosis of various malignancies, including leukemia, breast, and prostate cancer
Treatment with anti-VEGF targeting agents dramatically increases PIM kinase expression, and overexpression of PIM1 effectively blocks the ability of these drugs to prune tumor vasculature
Overexpression of PIM1, which is frequently observed in many solid tumors, regardless of hypoxia, could inhibit the canonical HIF-1 degradation pathway, representing a novel mechanism to explain the constitutive activation of HIF-1 observed in cancer
Summary
PIM kinase family members have been implicated as important factors in the progression and prognosis of various malignancies, including leukemia, breast, and prostate cancer. Casillas et al tested the hypothesis that PIM kinase could be responsible for imparting de novo and/or acquired resistance to anti-angiogenic agents, as these drugs are designed to disrupt vasculature, which increases hypoxic stress [3]. Treatment with anti-VEGF targeting agents dramatically increases PIM kinase expression, and overexpression of PIM1 effectively blocks the ability of these drugs to prune tumor vasculature.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
